
Sanofi Ventures
Corporate venture Arm of the French drugmaker Sanofi; an existing backer of T-Therapeutics.
Last refreshed: 14 November 2026
Why do big drugmakers keep buying into Cambridge T-cell receptor startups?
Timeline for Sanofi Ventures
T-Therapeutics raises $133m in Series B
UK Startups and InnovationBackground
Sanofi Ventures, the corporate venture Arm of the French drugmaker Sanofi, is an existing investor in T-Therapeutics, the Cambridge spinout that raised a $133m Series B on 5 November 2026. Its register mixes Advent Life Sciences, the British Business Bank, Eli Lilly, Johnson & Johnson's JJDC, Sanofi Ventures and Tencent, because no single investor class will fund drug development to proof of concept.
Sanofi itself has bought British biotech before: it acquired Kymab, a Cambridge antibody company, in 2021.
Is Sanofi an investor in T-Therapeutics?
What is Sanofi Ventures?
Has Sanofi bought a British biotech?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.